ARTICLE | Clinical News
Campath alemtuzumab regulatory update
October 30, 2000 8:00 AM UTC
The FDA's Oncologic Drugs Advisory Committee (ODAC) will review at its Dec. 13-14 meeting the companies' BLA for Campath to treat advanced B cell chronic lymphocytic leukemia resistant to existing the...